Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages

• Published in: Biochemical and biophysical research communications 2003-09, Vol.309 (2), p.414-418
• Main Authors: Katayama, Toyoko, Hayashi, Yasuhiro, Nagahira, Kazuhiro, Konishi, Kyoko, Yamaichi, Kozo, Oikawa, Shinzo
• Format: Article
• Language: English
• Subjects: Animals; Antiprotozoal Agents - pharmacology; Cell Line; Dose-Response Relationship, Drug; Female; IL-10; Imidocarb; Imidocarb - pharmacology; Inflammation; Interleukin-10 - biosynthesis; Interleukin-10 - blood; Lipopolysaccharides - pharmacology; LPS; Macrophages; Macrophages - drug effects; Macrophages - metabolism; Mice; Mice, Inbred BALB C; TNF-α; Up-Regulation - drug effects; Zymosan - pharmacology
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2003.08.017

Interleukin-10 (IL-10), a potent antiinflammatory and immunosuppressive cytokine, plays an important role in the regulation of immune responses. To discover small molecules that stimulate IL-10 production, a cell-based screening assay was performed using a murine macrophage cell line, RAW264.7. Imidocarb, (3,3 ′-bis-2-imidazolin-2-yl)-carbanilide, which has been used as an anti-protozoan drug for the prevention and treatment of babesiosis in cattle, was thus identified. Imidocarb markedly enhanced LPS-induced IL-10 production not only by RAW264.7 cells but also by murine peritoneal macrophages in a concentration-dependent manner. It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. In contrast, imidocarb inhibited LPS-induced tumor necrosis factor (TNF)-α production by peritoneal macrophages. In mice, intraperitoneal administration of imidocarb significantly increased serum IL-10 levels and lowered TNF-α levels. Our results suggest that a novel anti-inflammatory property of imidocarb could lead to new therapeutic approaches in inflammatory conditions.